The EMA said it made this decision after analyzing the results of a study of more than 5,000 people.
Article written by
Posted
Update
Reading time : 1 min.
The European Medicines Agency (EMA) said in a statement on Thursday March 24 that it recommended marketing for those over 12 years of age. “weighing at least 40 kg” AstraZeneca’s Evusheld preventive treatment against Covid-19. This treatment is intended for people who lack antibodies and whose body is resistant to vaccination. Evusheld combines two types of synthetic antibodies (tixagevimab and cilgavimab), and is administered as two intramuscular injections. It is considered effective against Omicron.
These antibodies help the immune system fight off the virus if it is encountered, by targeting its Spike protein, which allows it to enter cells to infect them. The European regulator assured that it had taken this decision after analyzing the results of a study on more than 5,000 people. “Evusheld’s safety profile was favorable and side effects were generally mild, with a small number of people experiencing reactions”added the EMA.
The regulator has concluded that the drug’s benefits outweigh its risks in approved use and will now send its recommendation to the European Commission for a rapid decision applicable in all EU member states.